PSAMP
JSPR icon

P. Schoenfeld Asset Management (PSAM)’s Jasper Therapeutics JSPR Stock Holding History

P. Schoenfeld Asset Management (PSAM)’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-47,500
Closed -$4.75M – 349
2020
Q4 		$4.75M Hold
47,500
– – 0.44% 47
2020
Q3 		$4.71M Buy
+47,500
New +$4.75M 0.45% 48

Other funds holding JSPR

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM)'s JSPR Position: Q1 2021 in Review

P. Schoenfeld Asset Management (PSAM) sold out of Jasper Therapeutics (JSPR) in Q1 2021, closing a stake of 47,500 shares — an estimated $4.75M sold.

P. Schoenfeld Asset Management (PSAM) first reported a position in JSPR in Q3 2020 and held it in 2 quarters. The position peaked at $4.75M in Q4 2020. 53 funds tracked by Wall St. Rank hold JSPR as of Q1 2021.

  • P. Schoenfeld Asset Management (PSAM) reported no remaining Jasper Therapeutics position as of Q1 2021 after selling out during the quarter.
  • P. Schoenfeld Asset Management (PSAM) sold 47,500 Jasper Therapeutics shares in Q1 2021, an estimated $4.75M.
  • P. Schoenfeld Asset Management (PSAM) first reported a position in Jasper Therapeutics in Q3 2020 and held it in 2 quarters.
  • P. Schoenfeld Asset Management (PSAM)'s Jasper Therapeutics position peaked at $4.75M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2021.

Based on P. Schoenfeld Asset Management (PSAM)'s 13F filing for Q1 2021, filed 14 May 2021.